Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 6/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.55 |
| ▸ | XIAP | P98170 | 5/20 | 0.51 |
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | PYGM | P11217 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 6/20 | 0.48 |
| ▸ | ACE | P12821 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655974 | 0.89 | RIPK1 (0.58) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL20344575 | 0.85 | RIPK1 (0.53) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL3924251 | 0.82 | RIPK1 (0.63) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL4218830 | 0.82 | RIPK1 (0.63) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL14376829 | 0.80 | RIPK1 (0.60) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL31655944 | 0.79 | RIPK1 (0.65) | RIPK1 | |
| SCHEMBL31656008 | 0.78 | RIPK1 (0.47) | RIPK1SCN9AXIAP | |
| SCHEMBL31655914 | 0.78 | XIAP (0.53) | RIPK1SCN9AXIAP | |
| SCHEMBL8670502 | 0.75 | SCN9A (0.55) | RIPK1SCN9AXIAPPYGLPYGM | |
| SCHEMBL19255017 | 0.75 | RIPK1 (0.70) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582414-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-07-09 | — | — | EP | claimed |
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | ARTIVILA BIOPHARMA (CN) | 2025-12-04 | — | — | US | disclosed |
| EP-4582414-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | Artivila Biopharma (CN) | 2025-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368633-A1 | AZEPINE FUSED RING COMPOUND AS RIPK1 INHIBITOR AND USE THEREOF | RIPK1, RIPK2, RIPK4 | RIPK1 1/4885SCN9A 3105/4885XIAP 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.